AIDS TREATMENT NEWS No. 070 - December 2, 1988
John S. James
In the future we will use "egg lecithin lipids" to refer generically to egg lecithin products (including AL 721) in which the 7: 2: 1 ratio of NL, PC, and PE is present or intended, and "AL 721" to refer to the Ethigen product.
There is more confusion. Ethigen Corp. will also introduce the same product under a new trademark name, "Altrigen", for over-the-counter sales in the U. S. It will continue to be called "AL 721" in clinical trials, and in Europe, where it is now available by prescription in England, although it cannot be promoted there until trials are complete.
The "Altrigen" name apparently resulted from a compromise with the FDA, which objects to products being sold as food sup- plements if they are also in clinical trials for approval as a drug. Ethigen will be allowed to sell its remaining stocks which are already labeled as "AL 721". Until recently, Ethigen was unable to speak publicly about this situation, due to its negotiations with the FDA.
You can order AL 721 (which will soon be called Altrigen) from Ethigen by calling 800/752-5721. You can obtain generic products through buyers' clubs (see list in AIDS Treatment News #69), or from some health-food stores.
EDITORIAL NOTE: The current situation with egg lecithin lipids is complex, ambiguous, and controversial. There is much speculation (but no compelling proof from scientific human tri- als) about whether this treatment works at all, or whether any particular version works best.
Our impression from talking with persons using this treat- ment, plus what little scientific clinical information is available, is that egg lecithin lipids are a significant help to some people. But we have also heard several reports of growing skepticism among physicians and others in New York, where more people are using the lipids than anywhere else. We will provide more information as it becomes available.
881202
ATN07006
Copyright © 1988 - AIDS Treatment News. Permission granted for noncommercial reproduction, provided that our address and phone number are included if more than short quotations are used. Subscription lists are kept confidential. AIDS Treatment News, Subscription and Editorial Office: 1233 Locust St., 5th floor Philadelphia, PA 19107 800/TREAT-1-2 toll-free email: aidsnews@critpath.org http://www.aidsnews.org
Subscription Information: Call 800/TREAT-1-2: Businesses, Institutions, Professionals: $270/year. Includes early delivery of an extra copy by email. Nonprofit organizations: $135/year. Includes early delivery of an extra copy by email. Individuals: $120/year, or $70 for six months. Special discount for persons with financial difficulties: $54/year, or $30 for six months. If you cannot afford a subscription, please write or call. Outside North, Central, or South America, add air mail postage: $20/year, $10 for six months. Back issues available. Fax subscriptions, bulk rates, and multiple subscriptions are available; contact our office for details. Please send U.S. funds: personal check or bank draft, international postal money order, or travelers checks. VISA, Mastercard, and purchase orders also accepted. ISSN # 1052-4207
AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 1988. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 1988. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .